.Charles Baum, M.D., Ph.D., that oversaw Mirati Rehabs’ $ 5.8 billion sale to Bristol Myers Squibb last year, is taking the reins of youthful biotech Terremoto Biosciences.Baum’s “considerable experience in drug development, and effective performance history beforehand high-impact medications, will certainly be instrumental,” outgoing CEO Peter Thompson, M.D., stated in a July 25 launch. Thompson will preserve his seat as board chairperson..Baum, a trained physician-scientist, was the founder, head of state as well as chief executive officer of oncology-focused Mirati. Just before that, he assisted build cancer medicines at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum will certainly act as chief executive officer at Terremoto, a provider cultivating small molecules to target disease-causing healthy proteins– like those found in malignant cyst tissues– making use of covalent connects. Existing therapies that use covalent connects predominantly target the amino acid cysteine. Having said that, of the twenty amino acids that compose proteins, cysteine is actually the least common.
Terremoto is actually instead targeting one of the essential amino acids, lysine, which is actually discovered in almost all proteins.By targeting lysine and various other amino acids, Terremoto wishes to manage formerly undruggable ailments and also develop first-in-class medications..The biotech, located in South San Francisco, brought up $75 thousand in series A backing in 2022. A little bit of more than a year later on, the biotech much more than increased that amount in a $175 thousand series B.